Source link : https://www.newshealth.biz/health-news/new-standard-for-unresectable-hepatocellular-carcinoma/
SAN FRANCISCO — After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed. Patients who received durvalumab (Imfinzi) plus bevacizumab (Avastin) in addition to TACE had a median progression-free survival (PFS) of 15.0 months as compared with 8.2 months for TACE […]
Author : News Health
Publish date : 2024-01-21 08:00:00
Copyright for syndicated content belongs to the linked Source.